BCL2L12 Human shRNA Plasmid Kit (Locus ID 83596)

CAT#: TF306421

BCL2L12 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector, 5µg of each construct provided

Specifications

Product Data

• Locus ID: 83596
• Vector: pRFP-C-RS
• E. coli Selection: Chloramphenicol (34 ug/ml)
• Mammalian Cell Selection: Puromycin
• Format: Retroviral plasmids
• Kit Components: BCL2L12 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector(Gene ID = 83596). 5µg purified plasmid DNA per construct
  29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.
• RefSeq: BC007724, NM_001040668, NM_001282516, NM_001282517, NM_001282519, NM_001282520, NM_001282521, NM_052842, NM_138639, NR_104200, NR_104201, NR_104202, NR_104203, NR_104204, NR_104205, NM_001040668.1, NM_138639.1, NM_001282517.1, NM_001282521.1, NM_001282520.1, NM_001282516.1, NM_001282519.1, BC104005, BC104004, BC104006
• UniProt ID: Q9HB09
• Summary: This gene encodes a member of a family of proteins containing a Bcl-2 homology domain 2 (BH2). The encoded protein is an anti-apoptotic factor that acts as an inhibitor of caspases 3 and 7 in the cytoplasm. In the nucleus, it binds to the p53 tumor suppressor protein, preventing its association with target genes. Overexpression of this gene has been detected in a number of different cancers. There is a pseudogene for this gene on chromosome 3. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2013]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).